Banque Cantonale Vaudoise Purchases Shares of 2,562 Charles River Laboratories International, Inc. (NYSE:CRL)

Key Points

• Banque Cantonale Vaudoise has acquired a new stake in Charles River Laboratories International, purchasing 2,562 shares valued at approximately $386,000.
• Other institutional investors, including D1 Capital Partners and Assenagon Asset Management, have also significantly increased their positions in Charles River Laboratories, which is now 98.91% owned by institutional investors.
• Charles River Laboratories reported a quarterly earnings per share of $2.34, surpassing analyst expectations, although revenue was down 2.7% compared to the previous year.

Banque Cantonale Vaudoise bought a new stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,562 shares of the medical research company's stock, valued at approximately $386,000.

A number of other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC raised its stake in Charles River Laboratories International by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 1,233,211 shares of the medical research company's stock valued at $227,042,000 after purchasing an additional 14,787 shares during the last quarter. Ariel Investments LLC grew its holdings in shares of Charles River Laboratories International by 18.9% during the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company's stock worth $197,029,000 after buying an additional 169,640 shares in the last quarter. Invesco Ltd. raised its position in shares of Charles River Laboratories International by 17.1% in the fourth quarter. Invesco Ltd. now owns 1,034,180 shares of the medical research company's stock valued at $190,910,000 after buying an additional 151,159 shares during the last quarter. Mackenzie Financial Corp lifted its stake in shares of Charles River Laboratories International by 2.6% in the first quarter. Mackenzie Financial Corp now owns 1,002,951 shares of the medical research company's stock worth $150,964,000 after buying an additional 25,878 shares in the last quarter. Finally, D1 Capital Partners L.P. acquired a new position in Charles River Laboratories International during the fourth quarter worth about $172,752,000. Institutional investors and hedge funds own 98.91% of the company's stock.

Charles River Laboratories International Trading Down 1.6%

CRL traded down $2.75 on Friday, hitting $166.89. The company had a trading volume of 821,687 shares, compared to its average volume of 824,309. The company's fifty day moving average price is $153.56 and its 200 day moving average price is $149.44. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $236.88. The company has a current ratio of 1.43, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. The firm has a market cap of $8.20 billion, a P/E ratio of -256.75, a PEG ratio of 5.65 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The business had revenue of $984.17 million during the quarter, compared to analysts' expectations of $942.34 million. During the same period last year, the business earned $2.27 earnings per share. The business's revenue for the quarter was down 2.7% on a year-over-year basis. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on CRL. Robert W. Baird increased their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. Barclays lifted their price objective on Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 8th. Redburn Atlantic raised Charles River Laboratories International from a "neutral" rating to a "buy" rating and lowered their price objective for the stock from $188.00 to $182.00 in a research note on Friday, May 23rd. Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Finally, Wall Street Zen lowered Charles River Laboratories International from a "buy" rating to a "hold" rating in a report on Saturday, July 5th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Charles River Laboratories International currently has an average rating of "Hold" and a consensus price target of $174.54.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president directly owned 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.30% of the company's stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).